Mark Watson

Tekla Healthcare Opportunities Fund operates as a closed-end investment fund and investment trust. The trust's investment objective is to seek current income and long-term capital appreciation through investing in companies engaged in the healthcare industry, including equity securities, debt securities and pooled investment vehicles. The Trust was founded on April 2, 2014 and is headquartered in Boston, MA.

BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.

Sykes Enterprises, Inc. engaged in the provision of multichannel demand generation and global customer engagement services. It operates through the following segments: Americas, Europe, the Middle East and Africa (EMEA), and Other. The Americas segment includes the United States, Canada, Latin America, Australia, and the Asia Pacific Rim; and offers outsourced customer engagement solutions and technical staffing. The EMEA segment covers outsourced customer engagement solutions and fulfilment services. The Other segment represents other items such as corporate and other costs, other income and expense, and income taxes. The company was founded by John H. Sykes in 1977 and was headquartered in Miami, FL.

H. Lee Moffitt Cancer Center & Research Institute, Inc. provides research & contributions to clinical trials, prevention and cancer control. The firm operates as National Cancer Institute (NCI) Comprehensive Cancer Center. The company was founded by Lee H. Moffitt in 1981 and is headquartered in Tampa, FL.